Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.
Study Goal
The researchers aimed to investigate the occurrence of adverse events associated with erythropoiesis-stimulating agents (ESAs) and iron therapy in preoperative anemia treatment.
Results Summary
The study found very low certainty evidence regarding the safety of ESA and/or iron therapy, with most adverse event data focusing on mortality, thromboembolic, infectious, cardiovascular, and gastrointestinal events. The high risk of bias and limitations in study design, data collection, and reporting contributed to the uncertainty.
Population
Adult elective surgery patients with preoperative anemia.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
iron supplementation | neutral | preoperative anemia treatment | patients with preoperative anemia | - | hallmark therapy | #1 |
erythropoiesis-stimulating agent (ESA) administration | neutral | preoperative anemia treatment | patients with preoperative anemia | - | hallmark therapy | #2 |
intravenous (IV) iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #3 |
oral iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #4 |
IV iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #5 |
usual care/no iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #6 |
IV ferric carboxymaltose | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #7 |
IV iron sucrose | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #8 |
ESA+iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #9 |
control (placebo and/or iron, no treatment) | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #10 |
ESA+IV iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #11 |
ESA+oral iron | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #12 |
ESA+IV iron (different ESA dosing regimens) | neutral | adverse events | adult elective surgery patients with preoperative anemia | - | compared to | #13 |
iron and/or ESAs | neutral | mortality/survival adverse events | adult elective surgery patients with preoperative anemia | - | investigated | #14 |
iron and/or ESAs | neutral | thromboembolic adverse events | adult elective surgery patients with preoperative anemia | - | investigated | #15 |
iron and/or ESAs | neutral | infectious adverse events | adult elective surgery patients with preoperative anemia | - | investigated | #16 |
iron and/or ESAs | neutral | cardiovascular adverse events | adult elective surgery patients with preoperative anemia | - | investigated | #17 |
iron and/or ESAs | neutral | gastrointestinal adverse events | adult elective surgery patients with preoperative anemia | - | investigated | #18 |
ESA and/or iron therapy | no change | adverse events | preoperatively anemic elective surgery patients | - | remains unclear if associated with | #19 |
BACKGROUND: Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anemia treatment, as reflected in a set of evidence-based treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs. METHODS: Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until 23 May 2022. Randomized controlled trials (RCTs), cohort, and case-control studies investigating any AE during or after iron and/or ESA administration in adult elective surgery patients with preoperative anemia were eligible for inclusion and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence. RESULTS: Data from 26 RCTs and 16 cohort studies involving a total of 6062 patients were extracted, on 6 treatment comparisons: (1) intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low certainty evidence was assigned to all but one outcome category. This uncertainty results from both the low quantity and quality of AE data due to the high risk of bias caused by limitations in the study design, data collection, and reporting. CONCLUSIONS: It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documentation, and reporting of AE data.